KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Gains from Sales and Divestitures (2010 - 2013)

Elevance Health (ELV) reported Gains from Sales and Divestitures of -$300000.0 for Q2 2013, up 85.0% year-over-year from -$162162.2 in Q2 2012, and little changed on a QoQ basis from -$300000.0 in Q1 2013.

Elevance Health (ELV) has 4 years of Gains from Sales and Divestitures data on file, last reported at -$300000.0 in Q2 2013.

  • Quarterly Gains from Sales and Divestitures rose 85.0% year-over-year to -$300000.0 in Q2 2013, while the trailing twelve-month figure through Jun 2013 was -$300000.0 (up 85.0% YoY) and the FY2012 annual result came in at -$3.5 million, down 294.44% from the prior year.
  • Gains from Sales and Divestitures was little changed at -$300000.0 in Q2 2013 per ELV's latest filing, from -$300000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.8 million in Q2 2011 and bottomed at -$3.5 million in Q4 2012.
  • The 4-year median for Gains from Sales and Divestitures is -$300000.0 (2013), against an average of -$418181.8.
  • The widest annual swing landed in 2011, when Gains from Sales and Divestitures jumped 220.0%; it then slumped 294.44% in 2012.
  • Tracing ELV's Gains from Sales and Divestitures over 4 years: stood at -$1.5 million in 2010, then jumped by 220.0% to $1.8 million in 2011, then tumbled by 294.44% to -$3.5 million in 2012, then surged by 91.43% to -$300000.0 in 2013.
  • Per Business Quant, the three latest ELV Gains from Sales and Divestitures figures stand at -$300000.0 (Q2 2013), -$300000.0 (Q1 2013), and -$3.5 million (Q4 2012).

Historic Data

Download Data 🔒
DateValue
Jun 30, 2013 -300,000.00
Jun 30, 2013 -300,000.00
Mar 31, 2013 -300,000.00
Mar 31, 2013 -300,000.00
Dec 31, 2012 -3.50 Mn
Dec 31, 2012 -3.50 Mn
Sep 30, 2012 -2.10 Mn
Sep 30, 2012 -2.10 Mn
Jun 30, 2012 -2.00 Mn
Jun 30, 2012 -2.00 Mn
Mar 31, 2012 -2.00 Mn
Mar 31, 2012 -2.00 Mn
Dec 31, 2011 1.80 Mn
Dec 31, 2011 1.80 Mn
Sep 30, 2011 1.80 Mn
Sep 30, 2011 1.80 Mn
Jun 30, 2011 1.80 Mn
Jun 30, 2011 1.80 Mn
Mar 31, 2011 1.70 Mn
Mar 31, 2011 1.70 Mn
Dec 31, 2010 -1.50 Mn
Dec 31, 2010 -1.50 Mn